Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactium is a **bioactive decapeptide complex** derived from the hydrolysis of **bovine milk alpha-S1 casein** (milk protein) that contains α-casozepine as its main active component. It is produced via food-grade tryptic hydrolysis and is marketed as a **dietary supplement** for managing stress, anxiety, sleep quality, and stress-related symptoms. Lactium does not possess sedative or addictive effects typical of benzodiazepines and is generally considered safe, with no major side effects reported at recommended dosages. Its **mechanism of action** involves binding to GABA-A receptors at the benzodiazepine site, modulating GABAergic neurotransmission, enhancing relaxation, and reducing stress-induced cortisol levels. It is not a pharmaceutical or prescription medication but a nutraceutical/functional food ingredient. It is used globally in various product formulations and has been tested in multiple clinical studies for stress reduction, sleep disorders, and psychodermatological conditions such as acne vulgaris[1][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactium.